Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

New switchable CAR-T therapy enters phase 1 trial for advanced breast cancer

The Calibr-Skaggs Institute for Innovative Medicines, the drug development division of Scripps Research, today announced a milestone in cancer treatment with the dosing of the first patient in a phase 1 trial (NCT06878248) evaluating CLBR001 + ABBV-461, a modular, switchable chimeric antigen receptor T cell (sCAR-T) therapy in patients with advanced or metastatic breast cancer who have no suitable treatment options.

18 Jun 2025

Sphere Bio expands operations in China

Sphere Bio, a leading provider of picodroplet-based microfluidics for functional single-cell analysis and isolation, today announced the appointment of Redbert Biotechnology (张伟) as its exclusive distribution partner in China.

17 Jun 2025

Paper-based devices show high accuracy in detecting asymptomatic malaria

Devices made with cheap strips of paper have outperformed two other testing methods in detecting malaria infection in asymptomatic people in Ghana – a diagnostic advance that could accelerate efforts to eliminate the disease, researchers say.

16 Jun 2025

Small antibodies provide broad protection against SARS coronaviruses

Scientists have discovered a unique class of small antibodies that are strongly protective against a wide range of SARS coronaviruses, including SARS-CoV-1 and numerous early and recent SARS-CoV-2 variants.

14 Jun 2025

WHO warns of ORVO as outbreaks surge and health risks rise

Oropouche virus poses a growing public health risk, with recent outbreaks in Brazil and Cuba. The WHO report calls for urgent global preparedness measures.

13 Jun 2025

How Fluidics is Powering Modern Healthcare and Medical Device Innovation

The future of fluidics in healthcare: Blake Webb shares trends in automation and microfluidics that are reshaping medical diagnostics and laboratory processes.

From Fluid Metering, Inc. 12 Jun 2025

Eva1 targeted CAR T cells successfully eliminate tumors in preclinical study

CAR-T cells are specialized immune cells genetically modified to recognize and attack cancer cells. Researchers at Nagoya University in Japan and their collaborators have developed new CAR-T cells to target malignant tumors.

11 Jun 2025

Centauri Therapeutics publishes proof-of-concept data demonstrating activity of a novel bifunctional immunotherapy against Gram-negative bacterial infections

Centauri Therapeutics Limited (Centauri), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, today announced the publication of a peer-reviewed study in The Journal of Immunology.

10 Jun 2025

Study reveals 15 hidden genetic risk factors for celiac disease

This comprehensive GWAS reveals 15 new genetic variants linked to celiac disease, offering insights for earlier detection and tailored treatment strategies.

9 Jun 2025

Scientists unlock potential of cytokine adjuvants in mRNA vaccines

In the quest to design vaccines that better help the body's immune system fight disease, scientists are always looking for more tools for their arsenal.

6 Jun 2025

Compact diagnostic platform enables rapid COVID-19 antibody testing from fingertip blood

Researchers from the Shenzhen Institutes of Advanced Technology (SIAT), Chinese Academy of Sciences, along with multiple collaborators, have developed a compact diagnostic platform that can evaluate antibody protection against COVID-19 using only a single microliter of fingertip blood.

5 Jun 2025

New data shows zigakibart sustains proteinuria remission and kidney function in IgA nephropathy

New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, reinforce its potential as a disease-modifying treatment for IgA nephropathy (IgAN).

5 Jun 2025

LabGenius Therapeutics appoints Dr. Angus Sinclair as Chief Scientific Officer

LabGenius Therapeutics (“LabGenius”) is a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimize complex therapeutic antibodies, including those with multispecific designs.

4 Jun 2025

Navigating the dual role of B cells in tumor immunity

B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).

3 Jun 2025

Individual immune variation shapes the evolution of influenza strains

A new study has shown that person-to-person variation in antibody immunity plays a key role in shaping which influenza (flu) strains dominate in a population.

3 Jun 2025

Real world data confirms effectiveness of nirsevimab in young infants with bronchiolitis

A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections (The drug has been approved at the European level to protect infants in their first season of exposure to the virus) to infants can halve hospitalizations for bronchiolitis.

3 Jun 2025

Waters introduces BioResolve Protein A Affinity Columns to accelerate antibody titer measurement, enhancing process agility and batch quality

Waters Corporation today announced the launch of the BioResolve™ Protein A Affinity Columns with MaxPeak™ Premier Technology, providing precise titer measurements.

From Waters Corporation 2 Jun 2025

First-in-class antibody-drug conjugate shows high response rates in rare blood cancer trial

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendric cell neoplasm (BPDCN), according to data from a Phase I/II study led by researchers from The University of Texas MD Anderson Cancer Center.

2 Jun 2025

Immunotherapy before surgery boosts long term survival in lung cancer, trial shows

Results from a phase 3 clinical trial published in the New England Journal of Medicine, today (June 2nd) show that patients with lung cancer who received an immunotherapy drug, nivolumab, along with standard chemotherapy before surgery had improved long term survival compared to those who received chemotherapy alone, at 5 years after completing treatment.

2 Jun 2025

Terbium therapy shows promise in fighting lymphoma

Radionuclide therapy with the radioactive element terbium could effectively combat lymphoma. This is demonstrated by promising results from experiments carried out at the Paul Scherrer Institute PSI in collaboration with Inselspital - Bern University Hospital.

2 Jun 2025